Please assess the completion status of the following clinical trial:

Trial Title: Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse AML

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients with refractory or relapse acute myeloid leukemia not in remission after 2 cycles of induction chemotherapy early relapse (1st remission less than 6 months) not in remission after 1 cycle of re-induction chemotherapy multiple relapse~* age 16-60 years~* with inform consent~* no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage~* HLA matched related (6/6) or unrelated donors (at least 8/10)~Exclusion Criteria:~* age less than 18 years or over 61 years~* liver function/renal function damage (over 2 X upper normal range)~* with mental disease

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- intensive chemo - RIC preparation (Type: EXPERIMENTAL): The intensive chemotherapy is composed of Fludarabine 35mg/m2 D1-5, high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.

Based on this trial design, predict the completion outcome and termination type (if applicable).